Antiobesity pharmacotherapy: new drugs and emerging targets
about
Advances in the Science, Treatment, and Prevention of the Disease of Obesity: Reflections From a Diabetes Care Editors' Expert ForumWeight Loss Pharmacotherapy: Brief Summary of the Clinical Literature and Comments on Racial DifferencesAcetylshikonin from Zicao Prevents Obesity in Rats on a High-Fat Diet by Inhibiting Lipid Accumulation and Inducing LipolysisThe burden of obesity in the current world and the new treatments available: focus on liraglutide 3.0 mg.Cholecystokinin-induced satiety, a key gut servomechanism that is affected by the membrane microenvironment of this receptorCan We Selectively Reduce Appetite for Energy-Dense Foods? An Overview of Pharmacological Strategies for Modification of Food Preference BehaviorDrug development strategies for the treatment of obesity: how to ensure efficacy, safety, and sustainable weight loss.Congenital Malformations and Consequential Epidemiology.Antiobesity strategy targets energy economy safeguards.ThermoMouse: an in vivo model to identify modulators of UCP1 expression in brown adipose tissue.Lightening up a notch: Notch regulation of energy metabolism.Diacylglycerol Lipase α Knockout Mice Demonstrate Metabolic and Behavioral Phenotypes Similar to Those of Cannabinoid Receptor 1 Knockout Mice.Weight maintenance: challenges, tools and strategies for primary care physiciansTargeting metabolic disorders by natural products.Endocrine disruptors alter social behaviors and indirectly influence social hierarchies via changes in body weight.A single oral dose of a polyglucosamine influences the bioavailability of [9-(14)C]-Oleic acid in adult female Göttingen minipigsPost-marketing withdrawal of anti-obesity medicinal products because of adverse drug reactions: a systematic reviewFatty Acid Transport Proteins: Targeting FATP2 as a Gatekeeper Involved in the Transport of Exogenous Fatty Acids.Treating epilepsy in the setting of medical comorbidities.Ghrelin receptor modulators: a patent review (2011 - 2014).New perspectives on the development of antiobesity drugs.Nitric Oxide Regulates Skeletal Muscle Fatigue, Fiber Type, Microtubule Organization, and Mitochondrial ATP Synthesis Efficiency Through cGMP-Dependent Mechanisms.TNP [N2-(m-Trifluorobenzyl), N6-(p-nitrobenzyl)purine] ameliorates diet induced obesity and insulin resistance via inhibition of the IP6K1 pathway.Evolution of pharmacological obesity treatments: focus on adverse side-effect profiles.Drugs to treat obesity: do they work?Harnessing glucagon-like peptide-1 receptor agonists for the pharmacological treatment of overweight and obesity.Effect of lorcaserin on glycemic parameters in patients with type 2 diabetes mellitus.Chemoprevention of obesity by dietary natural compounds targeting mitochondrial regulation.Emerging drugs for the treatment of obesity.The relationship between early weight loss and weight loss at 1 year with naltrexone ER/bupropion ER combination therapy.High molecular weight PEGylation of human pancreatic polypeptide at position 22 improves stability and reduces food intake in mice.Knockdown of the transcript of ERK in the brain modulates hypothalamic neuropeptide-mediated appetite control in amphetamine-treated rats.Type 2 Diabetes: Progress Made but Still a Long Road to Travel to Reduce Disease Burden.Phentermine plus topiramate for weight reduction: more tolerable and effective?Curcumin suppresses Notch‑1 signaling: Improvements in fatty liver and insulin resistance in rats.A Pilot Study Measuring The Novel Satiety Hormone, Pro-Uroguanylin, In Adolescents With And Without Obesity.Differential effects of selective agonists of neuromedin U1 and U2 receptors in obese and diabetic mice.Molecular insights provide the critical path to disease mitigation.Chimeric peptide EP45 as a dual agonist at GLP-1 and NPY2R receptors.Obesity management in Prader-Willi syndrome: current perspectives
P2860
Q26784022-99270C39-FEBB-48F4-9BAF-B1FD340732C4Q28088815-D3F07DE5-E122-4BE1-AA58-A368C0910634Q28552550-BED2540E-97DE-4B7F-9EE8-3529A40D0822Q33750634-B56B648E-0A76-4641-B9B7-333D00C25EE6Q33838127-C8616326-3E8F-4851-978C-A246A56D1CD1Q34501087-ADAD9F6D-3B88-4A71-9BA7-92EEFEF3F293Q34637579-6C4368E3-7E20-4D5A-B776-C5E70DD6A6B5Q35077898-0A86932A-5D83-41E8-831D-77BBABE2EFE6Q35399304-88AC4752-E12F-4D24-A4C7-8877C3461574Q35481073-8F460DDD-4CFF-4F9A-AB7D-94ED43DA54F0Q35606440-F2190AD8-3C8D-44BF-A8FE-E90DE04CDDE2Q35672654-9CB212E9-F0C8-48DE-93DF-3837AA8CA878Q35816619-3441FCCC-C2A6-40C3-8381-0B0AB78114AEQ35830892-57C016DD-3A0F-4928-BC00-951B24D3034FQ35913778-B10BE673-E480-40BC-88F5-679F19C2383CQ35962039-9FA50712-DA6D-4D40-962C-A67472F77622Q36206061-D537ED07-1249-4A6D-9A0E-6DF2E756D822Q37102291-9AC21F79-0A87-4936-8341-9A9602B5C6C7Q38214818-078217AA-09A0-4A63-8CC4-12C11CE83848Q38232345-52BFB068-9EE5-4663-ACEC-8AEB8B8A4930Q38397340-D567EC7E-8329-4CF3-ABE3-BB3D66FF873DQ38412804-63118DA3-6DD8-4844-BDA0-BA407530EFE2Q38435784-32F1EE7A-88A8-40BC-B193-C23458A6F6B7Q38758765-243D107E-75AE-4E38-BD80-DEE0489F177FQ38800281-11E9C4D6-D8E9-4CD1-ABA5-A3A5C321BFC1Q38820528-C1DF2F19-95B8-427F-8D6E-6757178BAB14Q38874390-8D91AE80-7350-4C65-B732-663375A63353Q39012540-B73B8BD1-08F1-4D7D-95EF-7D1EF20E2C48Q39031756-F10FD049-D56F-46A6-9913-6414F80063DFQ39666490-E25A3676-F1E7-4DF2-8510-143802D2B195Q42709946-936E2AEE-1BD2-454C-A25A-610285C630E1Q47320464-3D16AA88-F3A2-4458-ADF5-AE056C351E43Q47409034-E9182B56-2738-4F8A-AAA0-B5940DE9A8D6Q47412106-356C16B9-175F-4FA7-B6C8-0E9AFF075B8AQ47426820-CAEA576C-8DF2-408A-8FB6-F6B12036FD1DQ47587497-105931D4-215C-4190-8DBA-1D4DB2C39566Q47618753-16F7E584-6579-42AC-B788-B1D19BEDADE9Q48384103-528CA2B9-0DC4-484F-878E-76D349852C1BQ52680710-6AC4CC58-BB74-4450-A93E-6B7F7FED3981Q57483607-20514FD9-4A0E-4C02-94DC-C8E5B2B49998
P2860
Antiobesity pharmacotherapy: new drugs and emerging targets
description
2013 nî lūn-bûn
@nan
2013 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Antiobesity pharmacotherapy: new drugs and emerging targets
@ast
Antiobesity pharmacotherapy: new drugs and emerging targets
@en
type
label
Antiobesity pharmacotherapy: new drugs and emerging targets
@ast
Antiobesity pharmacotherapy: new drugs and emerging targets
@en
prefLabel
Antiobesity pharmacotherapy: new drugs and emerging targets
@ast
Antiobesity pharmacotherapy: new drugs and emerging targets
@en
P2093
P2860
P356
P1476
Antiobesity pharmacotherapy: new drugs and emerging targets
@en
P2093
P2860
P356
10.1038/CLPT.2013.204
P407
P577
2013-10-08T00:00:00Z